350
Participants
Start Date
January 4, 2019
Primary Completion Date
January 31, 2025
Study Completion Date
January 31, 2026
9-ING-41
Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
Gemcitabine - 21 day cycle
Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
Doxorubicin.
Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
Lomustine
Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
Carboplatin.
Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
Nab paclitaxel.
Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
Paclitaxel.
Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
Gemcitabine - 28 day cycle
Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
Irinotecan
Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
UZA- Antwerpen, Edegem
Imelda VZW, Bonheiden
UZ Leuven Gasthuisberg, Leuven
Institut Catala d'Oncologia, Barcelona
UZ Gent, Ghent
Columbia University- Irving Medical Center, New York
Stony Brook University Hospital, Stony Brook
Hopital de la Timone, Marseille
Allegheny Health Network, Pittsburgh
St. Luke's University Health Network, Bethlehem
Christiana Care Health Services, Newark
Sibley Memorial Hospital, Washington D.C.
Center Hospitalier Regional Universitaire de Besancon - Site Jean Minjoz, Besançon
West Virginia University, Morgantown
Prisma Health Cancer Institute, Greenville
Duke University Medical Center, Durham
Hospital Clinico U San Carlos (HSC), Madrid
START Madrid-HM CIOCC Hospital Universitario, Madrid
CHRU Brest Hopital Morvan, Brest
Institut Bergonie, Bordeaux
Miami Cancer Institute, Miami
Florida Cancer Specialists - North, St. Petersburg
Florida Cancer Specialists - South, Fort Myers
Sarah Cannon Research Institute- Tennessee Oncology-Nashville, Nashville
Vanderbilt-Ingram Cancer Center, Nashville
Baptist Clinical Research Institute, Memphis
West Cancer Center, Germantown
Insitut de Cancerologie de l'Ouest, Saint-Herblain
INCLIVA University of Valencia, Valencia
University of Michigan, Ann Arbor
Des Moines Oncology Research Association, Des Moines
UW Carbone Cancer Center, Madison
Institute de Cancerologie de Lorraine, Vandœuvre-lès-Nancy
MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC), Minneapolis
Mayo Clinic, Rochester
Sanford Research, Sioux Falls
Hopital Claude Huriez, Lille
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Kansas University Cancer Center, Kansas City
Ochsner Clinic Foundation, New Orleans
Texas Oncology- Charles A. Sammons Cancer Center, Dallas
UT Southwestern Medical Center, Dallas
Utah Cancer Specialists, Salt Lake City
Mayo Clinic, Phoenix
Arizona Oncology Associates, Tucson
The University of Arizona Cancer Center, Tucson
Comprehensive Cancer Centers of Nevada, Las Vegas
University of California Irvine Health, Orange
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Oregon Health and Science University, Portland
Fred Hutchinson Cancer Research Center, Seattle
Morristown Medical Center, Morristown
Capital Health Medical Center/ Hopewell, Pennington
MD Anderson Cancer Center at Cooper, Voorhees Township
Rhode Island Hospital, Providence
Cross Cancer Institute, Edmonton
QE II Health Sciences Centre, Halifax
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park
Jewish General Hospital, Montreal
McGill University Health Centre, Montreal
Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke
Netherlands Cancer Institute, Amsterdam
Fundacao Champalimaud, Lisbon
Hospital Da Luz, Lisbon
Centro Hospitalar Universitario Sao Joao, Porto
Vall d'Hebron Institute of Oncology, Barcelona
Lead Sponsor
Actuate Therapeutics Inc.
INDUSTRY